Manosuthi W, Kiertiburanakul S, Sungkanuparph S, Ruxrungtham K, Vibhagool A, Rattanasiri S, Thakkinstian A. Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicine: 48 weeks results. AIDS. 2006 Jan 2;20(1):131-2.
Snoeck J, Kantor R, Shafer RW, Van Laethem K, Deforche K, Carvalho AP, Wynhoven B, Soares MA, Cane P, Clarke J, Pillay C, Sirivichayakul S, Ariyoshi K, Hulguin A, Rudich H, Rodrigues R, Bouzas MB, Brun-Vezinet F, Reid C, Cahn P, Brigido LF, Grossman Z, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan RP, Camacho R, Schapiro JM, Katzenstein D, Vandamme AM. Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. Antimicrob Agents Chemother. 2006 Feb;50(2):694-701.
Gottfried TD, Mink RW, Phanuphak P. Calypte AWARE HIV-1/2 OMT antibody test using oral fluid: special challenges of rapid HIV testing in the developing world. Expert Rev Mol Diagn. 2006 Mar;6(2):139-44.
Gold J, Batterham MJ, Rekers H, Harms MK, Geurts TB, Helmyr PM, Silva de Mendonca J, Falleiros Carvalho LH, Panos G, Pinchera A, Aiuti F, Lee C, Horban A, Gatell J, Phanuphak P, Prasithsirikul W, Gazzard B, Bloch M, Danner SA; E-1696 Study Investigators. Effects of nandrolone decanoate compared with placebo or testosterone on HIV-associated wasting. HIV Med. 2006 Apr;7(3):146-55.
Boyd MA, Burger DM, Phanuphak P, Cooper DA. Maintenance of successful ritonavir-boosted indinavir and efavirenz therapy in an HIV-infected patient with tuberculosis. AIDS. 2006 Apr 24;20(7):1083-5.
Boyd MA, Srasuebkul P, Ruxrungtham K, Mackenzie PI, Uchaipichat V, Stek M Jr, Lange JM, Phanuphak P, Cooper DA, Udomuksorn W, Miners JO. Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet Genomics. 2006 May;16(5):321-9.
Boyd MA, Siangphoe U, Ruxrungtham K, Reiss P, Mahanontharit A, Lange JM, Phanuphak P, Cooper DA, Burger DM. The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity. J Antimicrob Chemother. 2006 Jun;57(6):1161-7. Epub 2006 Apr 4.
Cahn P, Cassetti I, Wood R, Phanuphak P, Shiveley L, Bethell RC, Sawyer J. Efficacy and tolerability of 10-day monotherapy with apricitabine in antiretroviral-naive, HIV-infected patients. A AIDS. 2006 Jun 12;20(9):1261-8.
Khongphatthanayothin M, Tantipaibulvut S, Nookai S, Chumchee P, Kaldor J, Phanuphak P. Demographic predictors of a positive HIV test result among clients attending a large metropolitan voluntary counselling and testing centre in Thailand. HIV Med. 2006 Jul;7(5):281-4.
Manosuthi W, Sungkanuparph S, Thakkinstian A, Rattanasiri S, Chaovavanich A, Prasithsirikul W, Likanonsakul S, Ruxrungtham K. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis. 2006 Jul 15;43(2):253-5. Epub 2006 Jun 12.
Ananworanich J, Gayet-Ageron A, Le Braz M, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawasdikul S, Sirivichayakul S, Cavassini M, Karrer U, Genne D, Nuesch R, Vernazza P, Bernasconi E, Leduc D, Satchell C, Yerly S, Perrin L, Hill A, Perneger T, Phanuphak P, Furrer H, Cooper D, Ruxrungtham K, Hirschel B; Staccato Study Group; Swiss HIV Cohort Study. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet. 2006 Aug 5;368(9534):459-65.
Avihingsanon A, Avihingsanon Y, Darnpornprasert P, Kerr S, Ungsedhapand C, Duncombe C, Ubolyam S, Ruxrungtham K, Phanuphak P. High prevalence of indinavir-associated renal complications in Thai HIV-infected patients.J Med Assoc Thai. 2006 Aug;89 Suppl 2:S21-7.
Boyd MA, Carr A, Ruxrungtham K, Srasuebkul P, Bien D, Law M, Wangsuphachart S, Krisanachinda A, Lerdlum S, Lange JM, Phanuphak P, Cooper DA, Reiss P. Changes in body composition and mitochondrial nucleic acid content in patients switched from failed nucleoside analogue therapy to ritonavir-boosted indinavir and efavirenz. J Infect Dis. 2006 Sep 1;194(5):642-50. Epub 2006 Jul 18. Erratum in: J Infect Dis. 2006 Sep 15;194(6):870.
Nuesch R, Srasuebkul P, Ananworanich J, Ruxrungtham K, Phanupak P, Duncombe C. Monitoring the toxicity of antiretroviral therapy in resource limited settings: a prospective clinical trial cohort in Thailand. J Antimicrob Chemother. 2006 Sep;58(3):637-44.
Pace C, Grady C, Wendler D, Bebchuk JD, Tavel JA, McNay LA, Forster HP, Killen J, Emanuel EJ. Post-trial access to tested interventions: the views of IRB/REC chair, investigators, and research participants in a multinational HIV/AIDS study. AIDS Res Hum Retroviruses. 2006 Sep;22(9):837-41.
Aurpibul L, Puthanakit T, Siriaksorn S, Sirisanthana T, Sirisanthana V. Prevalence of protective antibody against measles in HIV-infected children with immune recovery after highly active antiretroviral therapy. HIV Med. 2006 Oct;7(7):467-70.
Mansergh G, Naorat S, Jommaroeng R, Jenkins RA, Stall R, Jeeyapant S, Phanuphak P, Tappero JW, van Griensven F. Inconsistent condom use with steady and casual partners and associated factors among sexually-active men who have sex with men in Bangkok, Thailand. AIDS Behav. 2006 Nov;10(6):743-51.
Boyd MA, Dixit NM, Siangphoe U, Buss NE, Salgo MP, Lange JM, Phanuphak P, Cooper DA, Perelson AS, Ruxrungtham K. Viral decay dynamics in HIV-infected patients receiving ritonavir-boosted saquinavir and efavirenz with or without enfuvirtide: a randomized, controlled trial (HIV-NAT 012). J Infect Dis. 2006 Nov 1;194(9):1319-22. Epub 2006 Sep 25.
Koekkoek S, Eggermont L, De Sonneville L, Jupimai T, Wicharuk S, Apateerapong W, Chuenyam T, Lange J, Wit F, Pancharoen C, Phanuphak P, Ananworanich J. Effects of highly active antiretroviral therapy (HAART) on psychomotor performance in children with HIV disease. J Neurol. 2006 Dec;253(12):1615-24. Epub 2006 Nov 8.
Chetchotisakd P, Anunnatsiri S, Kiertiburanakul S, Sutthent R, Anekthananon T, Bowonwatanuwong C, Kowadisaiburana B, Supparatpinyo K, Horsakulthai M, Chasombat S, Ruxrungtham K; Study Team. High rate multiple drug resistances in HIV-infected patients failing nonnucleoside reverse transcriptase inhibitor regimens in Thailand, where subtype A/E is predominant. J Int Assoc Physicians AIDS Care (Chic). 2006 Dec;5(4):152-6.
Bunupuradah T, Wannachai S, Chuamchaitrakool A, Intasan J, Nuchapong T, Neiss W, Kramm K, Pancharoen C, Burger D, Ananworanich J. Use of taste-masking product, FLAVORx, to assist Thai children to ingest generic antiretrovirals. AIDS Res Ther. 2006 Dec 29;3:30.
Ananworanich J, Hirschel B, Sirivichayakul S, Ubolyam S, Jupimai T, Prasithsirikul W, Chetchotisakd P, Kiertiburanakul S, Munsakul W, Raksakulkarn P, Tansuphasawadikul S, Schutz M, Snowden W, Ruxrungtham K; Staccato Study Team. Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir. Antivir Ther. 2006;11(5):631-5.
Antiretroviral therapy for HIV infection in adults and adolescents. World Health Organization. 2006. Phanuphak P and Duncombe C have contributed to the writing of this book.
Antiretrovirals for HIV: a compilation of facts and product information. World Health Organization. 2006. Duncombe C one of the writers.
Boyd MA, Srasuebkul P, Khongphattanayothin M, Ruxrungtham K, Hassink EA, Duncombe CJ, Ubolyam S, Burger DM, Reiss P, Stek M Jr, Lange J, Cooper DA, Phanuphak P. Boosted versus unboosted indinavir with zidovudine and lamivudine in nucleoside pre-treated patients: a randomized, open-label trial with 112 weeks of follow-up (HIV-NAT 005). Antivir Ther. 2006;11(2):223-32.
Guidelines for the clinical management of hiv infection in children in myanmar. second edition. National AIDS/STD Prevention and Control Programme, Department of health, Ministry of health, Myanmar. November 2006. Editor: Duncombe C.
Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults. World Health Organization. 2006. Editor: Duncombe C.
Kerr S, Lange J, Cooper DA, Phanupak P, Ruxrungtham K. HIV-NAT Promoting Rational and Evidence-based Use of Antiretroviral Therapies. Clinical Trials in Asia Pacific 2006; 10(21):1229-1234.
Management of HIV infection and antiretroviral therapy in infants and children : a clinical manual. World Health Organization. 2006. Ananworanich J and Puthanakit T are major contributions in preparing guidelines.
Practical Handbook for the Clinical Management of HIV Infection in Adults and Children. World Health Organization. Contributing Editor, Duncombe C.